NOVANTA INC

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15(b) under the Securities Exchange Act of 1934 (the “Exchange Act”), our management carried out an evaluation, with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of October 2, 2026, the end of the period covered by this report. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of October 2, 2026.

Changes in Internal Control Over Financial Reporting

During the quarter ended October 2, 2026, we implemented a new financial and operation system at one of our sites as part of a multi-year phased implementation. In connection with this implementation, we modified certain processes and internal controls over financial reporting, and we will continue to do so as additional sites are transitioned to the new system. We have taken steps to preserve the effectiveness of our internal control over financial reporting during the transition.

On July 23, 2026, we completed the acquisition of Riverpoint Medical. We are integrating Riverpoint Medical into our internal control over financial reporting and expect this to continue over the next twelve months. Management expects to exclude Riverpoint Medical from its assessment of internal control over financial reporting as of December 31, 2026, as permitted by SEC staff guidance.

Except as described above, there has been no change in our internal control over financial reporting during the quarter ended October 2, 2026 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.